Home › Prostate Cancer › NCT03802851
HoLEP Prior to Radiation Therapy for Patients With LUTS/Retention and Concurrent Prostate Cancer
Recruiting
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * Patients must be 18 years of age or older * Patients must have bothersome lower urinary tract symptoms (LUTS), defined by American Urological Association Symptom Score (AUA SS) of greater than or equal to 15 and/or as defined by a post-void residual of greater than or equal to 350mL and/or as defined by catheter dependence * Patients must be diagnosed with prostate cancer by pathological tissue analysis * Patients must have elected for radiation with androgen deprivation therapy as the primary treatment modality for their prostate cancer Exclusion Criteria: * Patients who are under 18 years of age are not eligible * Patients who have a diagnosis of bladder cancer are not eligible. * Patients with prior treatment for prostate cancer are not eligible. * Patients with any type of prior prostate surgery (minimally invasive, endoscopic, or otherwise) including prior transurethral resection of the prostate (but excluding prior prostate biopsy) are ineligible. * Patients with known metastatic prostate cancer are ineligible * Patients who are enrolled in other surgical or international trials at the time of this study are not eligible
About the study
To determine if holmium laser enucleation of the prostate (HoLEP) for the treatment of lower urinary tract symptoms (LUTS) and/or urinary retention alters the treatment course for patients concurrently diagnosed with prostate cancer.
What is being tested
- Holmium Laser Enucleation of Prostate (HoLEP) (procedure)
Sponsor: University of Kansas Medical Center · Participants: 30 · Started: Sep 19, 2019
Contact the study team
- Jane Ledesma, BS · Phone: (913) 588-8721
Official record on ClinicalTrials.gov — NCT03802851
Locations in the U.S.
| Kansas | University of Kansas Health System, Kansas City |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.